Melodiol Global Health (STU:1X80) Cash-to-Debt : 0.07 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Melodiol Global Health Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Melodiol Global Health's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Melodiol Global Health couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Melodiol Global Health's Cash-to-Debt or its related term are showing as below:

STU:1X80' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 2.08 Max: No Debt
Current: 0.07

During the past 8 years, Melodiol Global Health's highest Cash to Debt Ratio was No Debt. The lowest was 0.07. And the median was 2.08.

STU:1X80's Cash-to-Debt is ranked worse than
88.06% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs STU:1X80: 0.07

Melodiol Global Health Cash-to-Debt Historical Data

The historical data trend for Melodiol Global Health's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Melodiol Global Health Cash-to-Debt Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.87

1.86

No Debt

0.21

0.07

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										No Debt	No Debt	0.21	0.10	0.07

Competitive Comparison of Melodiol Global Health's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Cash-to-Debt falls into.

Melodiol Global Health Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Melodiol Global Health's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.425	/	(5.869	+	0.052)
	=	0.07

Melodiol Global Health's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.425	/	(5.869	+	0.052)
	=	0.07

Melodiol Global Health (STU:1X80) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Melodiol Global Health Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (STU:1X80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (STU:1X80) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

COPHF:USA ME1:Australia

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (STU:1X80) Headlines

No Headlines